Navigation Links
Legacy® and Lung Cancer Alliance Hail the Release of New Study Showing Lung Cancer Screening is Cost Effective
Date:4/9/2012

WASHINGTON, April 9, 2012 /PRNewswire-USNewswire/ -- Legacy® and Lung Cancer Alliance hailed the results released today of an actuarial cost-benefit analysis conducted by Milliman Inc., an internationally recognized actuarial consulting firm, which show that screening 50-64 year olds at high risk for lung cancer with low-dose computed tomography (CT) scans can save more lives, and at lower cost than commonly used screening methods for other cancers.

(Logo: http://photos.prnewswire.com/prnh/20101101/DC86294LOGO)

The study was published today in the April 2012 edition of Health Affairs, the nation's leading peer-reviewed journal on domestic and international health policy. This analysis was commissioned by Legacy and Lung Cancer Alliance shortly after the National Cancer Institute announced the results of the National Lung Screening Trial (NLST) which proved that low dose CT screening could reduce lung cancer deaths by at least 20% in a high risk population of 55-74 year old current and former smokers. 

"There is reason to believe that comparative rates of lung cancer survival will be even greater than 20%," said Cheryl G. Healton, DrPH, president and CEO of Legacy, who reiterated that lung cancer is the nation's number one cancer killer of both men and women, accounting for 28% of all cancer deaths. 

Milliman focused its actuarial analysis on the cost and benefit of screening a commercially insured population of high-risk 50-64 year olds. The data indicated that CT screening would avoid 15,000 deaths a year in that population alone. Screening high risk populations older that 64 would save an even higher number of lives each year. The analysis factors in the cost of cessation help for current smokers who now constitute about one in three new cases of lung cancer.

The cost per life-year saved - a commonly used measurement of public health value – is under $19,000. By comparison, the cost per life year saved for mammography screening is $31,000 to $51,000 and for colorectal cancer screening is $19,000 to $29,000. A key consideration in health insurance is how a new benefit would impact the monthly cost to employers, which currently averages $300 a month or more for each person covered.

The cost of adding CT screening would be $0.76 per member per month. In 2006, the cost of breast screening was $2.50 per member per month and the cost for colon cancer screening $0.96, amounts conservatively equivalent to $3.16 and $1.20 in today's dollars. 

Laurie Fenton-Ambrose, President and CEO of Lung Cancer Alliance said, "The National Lung Cancer Screening Trial provided us with scientific validation that lung cancer screening saves lives. That was step one. Now we have actuarial validation that lung cancer screening is also cost effective. This is step two. Step three is providing this benefit responsibly to those at risk – now," she said.

Both Healton and Fenton-Ambrose reiterated the need to move forward aggressively to ensure that high quality lung cancer screening for high risk populations is embedded into the public health infrastructure so that fewer lives are needlessly lost to lung cancer.

Legacy® helps people live longer, healthier lives by building a world where young people reject tobacco and anyone can quit. Legacy's proven-effective and nationally recognized public education programs include truth®, the national youth smoking prevention campaign that has been cited as contributing to significant declines in youth smoking; EX®, an innovative public health program designed to speak to smokers in their own language and change the way they approach quitting; and research initiatives exploring the causes, consequences and approaches to reducing tobacco use. Located in Washington, D.C., the foundation was created as a result of the November 1998 Master Settlement Agreement (MSA) reached between attorneys general from 46 states, five U.S. territories and the tobacco industry. To learn more about Legacy's life-saving programs, visit www.LegacyForHealth.org.

Follow us on Twitter @legacyforhealth and Facebook www.Facebook.com/Legacy.

Lung Cancer Alliance, www.lungcanceralliance.org, is committed to ending injustice and saving lives through an alliance of advocacy, education and support. LCA provides live, real time support, referral and information services for patients, their loved ones and those at risk for lung cancer; conducts national awareness campaigns; and advocates for multiple millions in public health dollars for lung cancer research.


'/>"/>
SOURCE Legacy
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... May 2, 2016  Deerfield announced today it ... Graybug Vision, Inc. Graybug Vision is an early ... may transform care for ocular diseases including wet ... technology was first developed at Johns Hopkins University ... venture. Graybug Vision is developing ...
(Date:5/2/2016)... , May 2, 2016 ... to reach USD 11.1 billion by 2024, according ... Research, Inc. Major drivers of the sonography market ... areas and government recommendations for periodic ultrasound screenings ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
(Date:4/29/2016)... New Jersey , April 29, 2016 /PRNewswire/ ... Software Suite for Life Sciences, Product Development Capabilities ... Global Life Science Customer Base . ... solutions provider, today announced the acquisition of Skura ... a global leader in adaptive sales enablement technology ...
Breaking Medicine Technology:
(Date:5/3/2016)... Los Angeles, CA (PRWEB) , ... May 03, 2016 , ... ... Massage Chair with its user friendly Samsung tablet and exclusive Smart Application. The ... truly unbeatable massage. Starting each massage with a customized user profile and specialized massage ...
(Date:5/3/2016)... ... 03, 2016 , ... Intrigma, the leading provider of vital ... expanding its use of Intrigma’s cloud-based physician scheduling solution, Efficient Scheduler (a part ... The Portland, Oregon based health system conducted a one-year pilot of the Efficient ...
(Date:5/3/2016)... ... May 03, 2016 , ... Octo ... solutions and digital consulting services to the federal government, has been awarded a ... / Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program Executive ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... a special type of surgical procedure that can be used to diagnose and treat ... instruments can be inserted. These instruments include a special lighting system and lens that ...
(Date:5/3/2016)... ... 2016 , ... Branches, Inc. is proud to have been selected as a ... in South Miami. Macy’s is a wonderful community partner and has helped to support ... mentoring, enrichment and academic support to elementary students 5 days a week. Summer Shade, ...
Breaking Medicine News(10 mins):